Nantahala Capital Management Establishes 6.9% Stake in Keros Therapeutics (KROS)

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has filed a Schedule 13G indicating a new substantial holding in Keros Therapeutics, Inc. (KROS). As of March 31, 2026, the reporting persons collectively beneficially own 1,360,419 shares of common stock, representing 6.90% of the company's outstanding shares. The filing indicates that the shares are held by various funds and separately managed accounts under the control of Nantahala Capital Management. All reported shares are held with shared voting and dispositive power among the three reporting persons. This position was acquired in the ordinary course of business and is not intended to influence or change the control of the issuer. This filing marks a significant increase from a previous 0.0% ownership level, establishing the group as a major institutional shareholder in the Massachusetts-based biopharmaceutical company. The reporting persons have certified that the securities were not acquired for the purpose of participating in any transaction involving a change in corporate control.